科学家发现增强纳米药物靶向肿瘤细胞新策略

2019-07-29 佚名 上海药物所

实体瘤中肿瘤基质细胞和细胞外基质组成异常复杂的瘤内递送屏障,严重阻碍了药物在肿瘤组织中的渗透及其靶向肿瘤细胞的递送。同时,瘤内肿瘤细胞分布呈高度异质性,即使制备了纳米制剂也难以突破上述递送屏障靶向肿瘤细胞,严重影响了其临床治疗效果。

实体瘤中肿瘤基质细胞和细胞外基质组成异常复杂的瘤内递送屏障,严重阻碍了药物在肿瘤组织中的渗透及其靶向肿瘤细胞的递送。同时,瘤内肿瘤细胞分布呈高度异质性,即使制备了纳米制剂也难以突破上述递送屏障靶向肿瘤细胞,严重影响了其临床治疗效果。

针对上述难题,中国科学院上海药物研究所研究员张志文、李亚平领导团队利用仿生脂蛋白系统,通过光热效应破坏肿瘤基质屏障,提高纳米药物靶向肿瘤细胞。这一新策略可显着抑制乳腺癌的复发和转移。

该研究设计构建了仿生脂蛋白载体分别包载光敏剂DiR(D-bLP)和化疗药物DM1(M-bLP)。研究发现,D-bLP经静脉注射4T1肿瘤小鼠后能够高效靶向渗透其体内肿瘤组织,但在瘤内被TAM、CAF等基质细胞截留,无法到达肿瘤细胞区域。经808nm光照后,D-bLP产生的光热效应能够杀伤肿瘤基质细胞,破坏细胞外基质,从而突破肿瘤基质递送屏障。在此基础上,显着提高了二次注射的M-bLP在肿瘤组织的蓄积和渗透,使其到达瘤内肿瘤细胞区域的分布提高27倍,显着抑制了乳腺癌的复发和转移,效果显着优于脂质体对照组。

该研究揭示了肿瘤基质屏障对纳米药物瘤内分布的影响,提出并证实了通过调节肿瘤基质靶向肿瘤细胞递送的思路,为克服瘤内基质屏障靶向肿瘤细胞的药物递送提供了有意义的探索。

7月25日,《自然-通讯》杂志在线发表了该研究成果。该研究得到了国家重大科学研究计划、国家自然科学基金、中科院战略性先导科技专项(A类)和中科院青年创新促进会等的资助。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2019-08-03 1468d3cdm57暂无昵称

    希望尽快能走到临床

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2019-07-31 xugc
  7. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1802618, encodeId=95a218026182f, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 26 02:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811378, encodeId=5b9918113e81c, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Mar 03 16:59:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804623, encodeId=8dba180462303, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jan 02 02:59:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370688, encodeId=919e3e068836, content=希望尽快能走到临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/24/3a76651e66b8a1e4be36a918b845e806.jpg, createdBy=51495147771, createdName=1468d3cdm57暂无昵称, createdTime=Sat Aug 03 07:39:46 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313044, encodeId=bb9213130442a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475690, encodeId=911d14e569022, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478436, encodeId=d7ef14e843631, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Jul 31 04:59:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370485, encodeId=48883e04854d, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Jul 30 06:49:38 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2019-07-30 txqjm

    谢谢了,学习

    0

相关资讯

Nano Lett:抗肿瘤纳米药物递送系统方面新进展

近日,纳米领域权威期刊《纳米快报》(Nano Letters)刊发了华中科技大学生命科学与技术学院、国家纳米药物工程技术研究中心杨祥良教授团队题为“Hydrophobicity-Adaptive Nanogels for Programmed Anticancer Drug Delivery”的研究论文。

上海药物所发现纳米药物载体递送力学机制

中科院上海药物所甘勇课题组与国家纳米科学中心施兴华团队合作,深入解析了纳米药物载体的力学性能对于克服多重生理屏障的影响。相关成果日前在线发表于《自然—通讯》杂志。

Adv Mater:报道华东理工一氧化氮抗肿瘤纳米药物研究新进展

李永生教授团队在一氧化氮(NO)抗肿瘤纳米药物领域研究取得新进展,相关工作成果以“Dual intratumoral redox/enzyme-responsive NO-releasing nanomedicine for the specific, high-efficacy and low-toxic cancer therapy”为题,在线发表于Advanced Materials上。

Biomaterials:沈华浩团队发现纳米药物有望成为治疗哮喘的潜在靶向新药

近日,浙江大学医学院附属第二医院呼吸与危重症医学科沈华浩、应颂敏教授团队与浙江大学药学院凌代舜教授团队通过多学科交叉研究发现:Bcl-2抑制剂小分子的纳米型药物能够很好的治疗哮喘的气道炎症和气道高反应性

Sci Tran Med:突破!纳米药物可治疗心脏疾病

近年来,纳米颗粒已被用于载药系统,负责将药物输送到身体的特定部位。这种疗法通常是口服或静脉注射,但往往心脏药物输送效率低下。为此,研究人员开发出了一种可吸入式纳米药物,这使得它们能够更快地到达心脏并被心肌细胞吸收,最终改善心脏功能。

Adv Healthc Mater:转铁蛋白(Tf)修饰的聚乙二醇化石墨烯(PG)载体携带纳米药物高度靶向治疗脉络膜黑素瘤

温州医科大学眼视光学与视觉科学国家重点实验室的Zhao B等近日在Adv Healthc Mater发表了一篇文章,他们介绍了转铁蛋白(Tf)修饰的聚乙二醇化石墨烯(PG)的合成,及其作为治疗眼脉络膜黑素瘤-1(OCM-1)细胞的高效药物递送载体的可行性。